Clinical trial
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
NCT00530816 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- Amgen
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2007
- Completion date
- July 31, 2013
- Enrollment
- 164 (actual)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.